In this episode of “Moving Medicine Forward” – The Podcast, Lily McNally and Heidi Shenk from the American Brain Tumor Association (ABTA) share their personal connections to brain tumors and discuss the ABTA’s resources, research initiatives, and community partnerships. They also discuss ABTA’s “Meet Hope Head On” campaign to triple research funding and expand patient outreach. Tune in to learn how the ABTA is advancing brain tumor research and how you can get involved or donate: CTI Cares Employee Fund

0:23 Meet our guests from the American Brain Tumor Association (ABTA), Lily McNally and Heidi Shenk, who share their personal stories and connection to the organization.

0:52 Heidi discusses her personal experience with brain tumors and how it led her to become involved with the ABTA.

3:11 Lily shares her journey and how her family's experience with brain tumors inspired her to contribute to the mission of the ABTA.

4:33 Heidi and Lily talk about how their families became involved with the ABTA and its supportive community.

7:21 Learn about the various resources the ABTA offers to patients and families, and how these services have personally benefited Heidi and Lily. For help, call the ABTA Care Line: 800-886-ABTA(2282).

11:36 Heidi and Lily explain ABTA’s partnerships with marathons, including Cincinnati’s Flying Pig, and how local events support their mission.

13:47 Discover how physicians, alumni, and others can contribute to the ABTA’s efforts, including its annual national conference. [Learn more about the Alumni Research Network (AARN): ABTA Alumni Research Network - Learn More or Donate Today!]

15:43 The ABTA’s 5-year campaign, Meet Hope Head On, aims to triple research funding, double patient outreach, and increase federal funding for oncology research. [Link to donate: CTI Cares Employee Fund]

17:15 Discover how the ABTA partners with clinical research organizations like CTI to help patients access clinical trials and advance treatment options. [Link to Clinical Trial Finder: Home | ClinicalTrials.gov]

19:45 In August 2024, the FDA approved a new treatment for low-grade glioblastomas. [Get the latest information on this treatment: VORANIGO® (vorasidenib) | For Grade 2 IDH-Mutant Glioma]

In this episode of "Moving Medicine Forward" - The Podcast, Greg Ruf, Founder & Executive Director of the DCM Foundation, and Bret Marshall, Senior Director of Business Development & Client Management at CTI, discuss the vital role of patient advocacy groups and the partnership between CTI and the DCM Foundation. Greg shares his journey in founding the DCM Foundation, and they explore key projects, achievements, and strategies for patient education and sponsor engagement. Tune in to learn how collaboration can enhance clinical research and advance patient advocacy.

0:24 Introduction of guests Greg Ruf and Bret Marshall.

1:06 Explanation of patient advocacy groups.

2:30 Overview of CTI and DCM Foundation partnership.

3:22 Greg’s journey in founding the DCM Foundation.

4:41 CTI's criteria for selecting advocacy group partners.

6:30 Highlights of joint projects and initiatives with DCM Foundation.

8:33 Key achievements of the DCM Foundation.

13:28 Methods used by the DCM Foundation to educate patients.

18:20 Ways for listeners to contribute.

23:16 Discussion on the timing of genetic testing.

25:40 Strategies to engage sponsors with advocacy groups.

28:36 How the DCM Foundation connects with patients.

34:42 Advice for enhancing collaboration between CROs, pharma, and advocacy groups.

In this special 25th-anniversary episode of "Moving Medicine Forward" - The Podcast, we're excited to welcome Tim Schroeder, Chief Executive Officer of CTI, Lynn Fallon, CTI Board Member and former President, and Kevin Schwarz, Chief Operating Officer of CTI. They share insights into CTI’s founding vision and its evolution over the past quarter-century. Tim and Kevin also discuss how CTI has driven innovation and contributed to the growth of the clinical research industry, highlighting key milestones such as their involvement in over 200 drug approvals. Join us as we celebrate this milestone and explore CTI's journey!

In this episode of "Moving Medicine Forward" – The Podcast, Dr. Monica Shah, Chief Medical Officer at CTI, discusses her journey into clinical research and her transition into her new role. Dr. Shah shares her immediate priorities and goals as CMO, her leadership style, and her approach to fostering collaboration within CTI. She also expresses her enthusiasm for the upcoming ARM Cell & Gene Meeting on the Mesa, highlighting the key topics and discussions she anticipates. Tune in to gain insights into Dr. Shah’s vision for her role at CTI and learn about her personal interests outside of work.

0:25 Meet Today’s Guest: Dr. Monica Shah, Chief Medical Officer at CTI.

0:30 Dr. Shah delves into her background and her journey into the field of clinical research.

6:50 Dr. Shah outlines her immediate priorities and goals as the new CMO.

8:05 Dr. Shah’s leadership style and how she plans to foster collaboration at CTI.

8:55 Dr. Shah shares her excitement about the upcoming ARM Cell & Gene Meeting on the Mesa.

10:20 Insights into the key topics and discussions Dr. Shah anticipates at the Meeting on the Mesa.

12:48 Dr. Shah reveals what she’s most excited about in joining the CTI team.

13:24 Learn about Dr. Shah’s interests and passions outside of her professional life.

In this episode we delve into the world of regulatory interactions, strategy, & operations with two industry leaders: Dr. Monica Rodriguez, Executive Director of Model-Informed Development, & Christine Norman-Tiner, Executive Director of Global Regulatory & Scientific Affairs. They share their invaluable expertise on:

• Developing effective regulatory strategies for clinical trials

• Navigating challenges in global regulatory communications

• The influence of model-informed development on regulatory practices

Explore how emerging technologies, patient-centric trials, & real-world evidence are transforming the biotech landscape.

In episode 6 of Moving Medicine Forward, we dive into diversity in clinical research with insights from CTI’s CEO Tim Schroeder and Board Member Dr. Bill Fitzsimmons. Hear about Bill's journey into clinical research, the importance of diversity in clinical trials, and strategies to overcome medical mistrust. We also discuss the latest FDA guidance on diversity* and CTI’s initiatives to foster inclusive practices.

0:29 - Introduction of guests, Tim Schroeder, CEO of CTI, and Bill Fitzsimmons, CTI Board Member.

2:20 - Bill shares his journey into clinical research and how he became involved with CTI.

2:45 - Bill's role and responsibilities as a CTI board member.

3:36 - Defining diversity in clinical research.

4:10 - The importance of diversity in clinical trials.

7:15 - Strategies to encourage participation in clinical trials despite medical mistrust.

12:54 - Reference to Adam Roth’s episode on vaccine trials during COVID-19: Clinical Research Site Spotlight - Vaccine Trials by Moving Medicine Forward (spotify.com)

13:00 - Challenges in maintaining diversity within clinical trials.

14:52 - Impact of regulations and strict requirements for diverse populations on the clinical trial process.

*15:15 - The FDA guidance on diversity in clinical trials mentioned during the episode has since been published. Please note that the episode was recorded prior to its release.

19:23 - Essential support needed for clinical trial sites to successfully recruit diverse populations.

20:57 - Role of CROs in supporting sites to recruit diverse populations.

23:38 - Improving health and research literacy to enhance participation.

28:56 - CTI’s initiatives to enhance diversity in clinical research.

Episode 5 assembles experts in transplantation. Tim Schroeder and Dr. Bill Fitzsimmons join us to discuss how CTI has been a key player in the field of transplantation, current trends, and where the future of transplantation is heading. Dr. Robert Gatson discusses transplantation innovations and his own background in the field.

Episode 4 assembles various CTI experts to discuss Cell and Gene Therapy. In episode 4, Bret Marshall, joins us to discuss CTI’s involvement in Cardiac Cell and Gene trials, our impact, and goals, as well as the current industry trends and advocacy groups. Jaclyn Guillory discussed the groundbreaking advancements in targeted therapies for KRAS mutations. Later in the episode, Michael Schmidt and Nicole Sparshott joined to discuss cell product chain of custody. Concluding with Joana Lancastre’s discussion on feasibility in cell and gene therapy.